Stock Quote
Salix Pharmaceuticals Ltd (SLXP.O) (Nasdaq)
$23.29
2:17pm EST
-0.51%
$23.41
$23.68
468,231
$24.29
$23.23
$24.23
$6.14
0.91
1,134,659
SLXP.O
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Chappell, John | Chairman of the Board | -- |
| Logan, Carolyn | President, Chief Executive Officer, Director | 1,603,970 |
| Derbyshire, Adam | Chief Financial Officer, Senior Vice President - Finance and Administration | 689,063 |
Profile
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company focuses on acquiring, developing and commercializing prescription drugs used in the treatment of a range of gastrointestinal diseases, which are those affecting the digestive tract. As of December 31, 2008, the Company’s products were... Full Description
Company Address
Salix Pharmaceuticals Ltd
1700, Perimeter Park Drive
Morrisville NC 27560
P: +1919.8621000
F: +1919.8621095
1700, Perimeter Park Drive
Morrisville NC 27560
P: +1919.8621000
F: +1919.8621095
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| GlaxoSmithKline plc | £1,277.50 | +24.00 |
| Solvay S.A. | €71.92 | +1.25 |
| The Procter & Gamble Company | $62.84 | +1.04 |
| SLXP.O | Industry | |
|---|---|---|
| P/E(TTM) | -- | 3.57 |
| P/S(TTM) | 5.17 | 0.57 |
| ROI(TTM) | -14.34 | 1.86 |
| ROE(TTM) | -18.97 | 2.51 |
| Consensus Recommendation | Outperform |
|---|---|
| EPS Est. (Current Period) | -- |
| EPS Est. (Current Year) | -- |
| Total Revenue | $65.66M |
| Net Income | $-7.32M |
| EPS | $-0.15 |
